Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518362 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1NPBWR1 | |
| SCHEMBL4190199 | 0.84 | PTGS2 (0.73) | PTGS2PTGS1NPBWR1 | |
| SCHEMBL4182604 | 0.83 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL4194004 | 0.82 | PTGS2 (0.83) | PTGS2PTGS1NPBWR1 | |
| SCHEMBL6601664 | 0.82 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL6601374 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4188328 | 0.82 | PTGS2 (0.69) | PTGS2PTGS1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4195994 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL4184783 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1NPBWR1 | |
| SCHEMBL6603593 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | claimed |
| EP-0975604-B1 | PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC (CA) | 2004-07-21 | — | — | EP | claimed |
| WO-2004056376-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING NITRATE | NITRICARE HB (SE) | 2004-07-08 | — | — | WO | claimed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | claimed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | claimed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | claimed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | claimed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | claimed |
| US-6004960-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA, INC. (CA) | 1999-12-21 | — | — | US | claimed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A | 2009-02-12 | — | — | US | disclosed |
| WO-2007129169-A2 | COX- II INHIBITORS FOR IMPROVING REPRODUCTIVE SUCCESS IN A FEMALE ANIMAL | PFIZER LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| EP-0975604-A1 | PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2 | Merck Frosst Canada & Co. (CA) | 2000-02-02 | — | — | EP | disclosed |
| US-6004960-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA, INC. (CA) | 1999-12-21 | — | — | US | disclosed |
| WO-1998041511-A1 | PYRIDAZINONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | PTGS2 3/4885PTGS1 1/4885HSP90AA1 730/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | PTGS2 3/4885PTGS1 1/4885HSP90AA1 784/4885 |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGIS, PTGS1, PTGS2 | PTGS2 3/4885PTGS1 2/4885HSP90AA1 826/4885 |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | PTGS2 3/4885PTGS1 1/4885HSP90AA1 784/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | PTGS2 3/4885PTGS1 1/4885HSP90AA1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.